Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building,
CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago,
UC = Conference Chicago at University Center
* = applied session ! = JSM meeting theme
Activity Details
500 * !
Wed, 8/3/2016,
8:30 AM -
10:20 AM
CC-W175c
Adaptive Designs: Interim Decision Making — Contributed Papers
Biopharmaceutical Section
Chair(s): Weili He, Merck
8:35 AM
Unblinded Sample Size Re-Estimation in Bioequivalence Trials with Small Sample Sizes
—
Sam Hsiao, Cytel ; Lingyun Liu, Cytel
8:50 AM
Multiple Testing Procedures for Adaptive Enrichment Designs: Combining Group Sequential and Reallocation Approaches
—
Michael Rosenblum, Johns Hopkins Bloomberg School of Public Health ; Tianchen Qian, Johns Hopkins Bloomberg School of Public Health ; Yu Du, Johns Hopkins Bloomberg School of Public Health ; Huitong Qiu, Johns Hopkins Bloomberg School of Public Health ; Aaron Fisher, The Johns Hopkins University
9:05 AM
Blinded Sample Size Re-Estimation in Demonstrating Biosimilarity
—
Lingyun Liu, Cytel ; Emmanuelle Vincent, Cytel
9:20 AM
Sample Size Re-Estimation in a Two-Stage Cross-Over Trial for Testing for Average Bioequivalence
—
Byron Jones, Novartis Pharma ; Will Maurer, Novartis Pharma AG ; Ying Chen, Shanghai University of Finance and Economics
9:35 AM
Adaptive Enrichment with Subpopulation Selection at Interim
—
Xiang Ling, FDA/CDER ; Sue-Jane Wang, FDA ; Kun Jin, FDA/CDER ; Hsien-Ming James Hung, FDA
9:50 AM
Improved Group Sequential Clinical Trial Designs with Multiple Co-Primary Endpoints
—
Koko Asakura, National Cerebral and Cardiovascular Center ; Toshimitsu Hamasaki, National Cerebral and Cardiovascular Center ; Franz Koenig, Medical University of Vienna ; Martin Posch, Medical University of Vienna
10:05 AM
Arm Dropping in Clinical Trials: An In-Depth Look at Statistical Considerations and Implications
—
JonDavid Sparks, Eli Lilly and Company ; Brian Millen, Eli Lilly and Company ; Qi Zhang, Eli Lilly and Company
